drugset / Trial / NCT00399945

Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study

NCT00399945

Phase 1 Completed 12 enrolled Novartis
RandomizedCrossoverOpen-labelTreatment

Summary

This study assesses the aerosol delivery characteristics (measured by in vivo lung deposition, nebulization time, serum tobramycin concentrations, and pharmacokinetic parameters) and safety of tobramycin inhalation solution administered for inhalation by PARI eFlow rapid electronic nebulizer (no compressor) vs. PARI LC PLUS Jet Nebulizer (with compressor) in healthy subjects and in subjects with cystic fibrosis.

Timeline

Start
2006-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule Inhaled

Indications